Sosei Subsidiaries Heptares to Acquire G7 Therapeutics to Extend Leadership in GPCR-focused Drug Discovery and Development

TOKYO–(BUSINESS WIRE)–Sosei Group Corporation (“Sosei”; TOKYO Mothers Index: 4565) today announces that Heptares Therapeutics (“Heptares”), the wholly-owned subsidiary of Sosei, has signed a share purchase agreement that will allow the acquisition of 100% in G7 Therapeutics, a privately held drug discovery and development company based in Switzerland, for CHF 12 million cash. The strategic acquisition broadens and strengthens Heptares’ intellectual property and platform for structure-based dr
Source: BusinessWire-Primary

Sosei Subsidiaries Heptares to Acquire G7 Therapeutics to Extend Leadership in GPCR-focused Drug Discovery and Development